Navigating the Patient Journey in Chronic Lymphocytic Leukemia: Oncology Nurse Strategies in Therapy Management

Nurse and physician expert faculty will discuss the emerging advances in the treatment of chronic lymphocytic leukemia (CLL) with novel agents targeting the B-cell receptor (BCR) pathway, and the latest, top-line safety and efficacy trial data for monotherapy and combination therapy strategies for CLL in first- and later-line settings. Attendees will understand how to differentiate between the different novel agents available with regard to efficacy, adverse event profile, and other relevant clinical factors. There will also be discussion on strategies to optimize patient satisfaction and communication by addressing clinical challenges, promotion of patient adherence, proper management of adverse events, and the encouragement of open communication between provider and patient. This educational initiative will be interactive, with attendees following the patient journey through real-world patient cases and polling questions incorporated throughout.


Presented by Creative Educational Concepts, Inc.

Supported through an independent educational grant from AstraZeneca.

Target Audience

This activity is designed to meet the educational needs of oncology nurses and nurse practitioners attending local ONS Chapter Meetings across the U.S.

Learning Objectives

  • Review the role of the BCR (B-cell receptor) pathway in CLL development and examine currently available and emerging novel therapies targeting the BCR pathway.
  • Appraise the appropriate selection and sequencing of CLL therapy based on current guideline recommendations and patient-specific factors such as line and duration of therapy, clinical presentation, mutation status, among others.
  • Discuss unique differences between novel therapies, strategies to properly monitor and manage toxicities, and key counseling points to discuss with patients to ensure minimization of toxicities and optimization of oral adherence.
  • Explore strategies to ensure patient understanding and empowerment about their treatment plan and ways to encourage open communication between patient and provider to optimize outcomes.

Additional Information

AttachmentSize
PDF icon Slide Handout5.21 MB
PDF icon General Information604.29 KB
PDF icon Evaluation and CE Form97.86 KB
PDF icon How to Request Credit316.71 KB
Course summary
Available credit: 
  • 1.00 ANCC
    • 0.75 ANCC Pharmacology Contact Hours
  • 1.00 Participation
Course opens: 
06/22/2021
Course expires: 
11/11/2021
Rating: 
0

5 min      Welcome and Introductions/Pre-test
10 min    Exploring the BCR Pathway in Chronic Lymphocytic Leukemia: Novel Therapies at the Forefront
40 min    Collaborative Decision-Making and Optimization of Patient Outcomes in CLL: Patient Cases for the Oncology Nurse
5 min      Conversations with the Experts and Q&A/Post-test

JW Marriott LA Live
8:50AM PT
Los Angeles, CA
United States

Shazia K Nakhoda, MD
Assistant Professor, Department of Hematology/Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania 

 


Dr. Nakhoda is an assistant professor in the Department of Hematology/Oncology at Fox Chase Cancer Center. She specializes in B-cell lymphomas and leukemias. She has particular interest in improving toxicities associated with cancer therapeutics in lymphoma. She completed her internal medicine residency at University of Maryland and her Hematology/Oncology fellowship at Fox Chase Cancer Center.

 

Barbara Rogers, CRNP, MN, AOCN, ANP-BC
Adult Hematology-Oncology Nurse Practitioner
Fox Chase Cancer Center
Philadelphia, Pennsylvania

 


Ms. Rogers is a Nurse Practitioner at Fox Chase Cancer Center in Philadelphia, Pennsylvania. She obtained her BSN from Trenton State College, her MN from UCLA and her post-master’s NP certificate from Temple University. Ms. Rogers has over 40 years of oncology experience with most of that time focused on the care of patients with hematologic malignancies. She has
authored many peer-reviewed journal articles and book chapters, as well as given many presentations related to the care of patients with hematologic malignancies and symptom management. Ms. Rogers has held leadership positions in multiple organizations such as serving on the ONS Board of Directors, Chair of the ONS Nominating Committee, and Chair of the Advanced Practice Test Development Committee of the Oncology Nursing Certification Corporation. Currently, she is a member of the Education Committee of the Advanced Practitioner Society for Hematology and Oncology (APSHO).


In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Planners:  
Vanessa Carranza, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.

Katherine L. Byar, MSN, ANP-BC, BMTCN–has no relevant financial relationships to disclose in relation to the content of this activity.

Matthew Lunning, DO–has disclosed that he is a consultant for Acrotech, ADC Therapeutics, AstraZeneca, BeiGene, BMS, Daiichi Sankyo, Janssen, Karyopharm, Kite, Kyowa Kirin, Legend, Morphosys, Myeloid Therapeutics, Novartis, Spectrum, and TG Therapeutics.
 
Authors/Presenters:
Katherine L. Byar, MSN, ANP-BC, BMTCN–has no relevant financial relationships to disclose in relation to the content of this activity.

Ian W. Flinn, MD, PhD–has disclosed that he is a consultant for AbbVie, AstraZeneca, BeiGene, Genentech, Gilead Sciences, Great Point Partners, Iksuda Therapeutics, Janssen, Juno Therapeutics, Kite Pharma, MorphoSys, Novartis, Nurix Therapeutics, Pharmacyclics, Roche, Seattle Genetics, Takeda, TG Therapeutics, Unum Therapeutics, Verastem, Vincerx Pharma, and Yingli Pharmceuticals but his honorarium is issued to his institution, Sarah Cannon Research Institute. He receives grant/research support from AbbVie, Acerta Pharma, Agios, ArQule, AstraZeneca, BeiGene, Calithera Biosciences, Celgene, Constellation Pharmaceuticals, Curis, Forma Therapeutics, Forty Seven, Genentech, Gilead Sciences, IGM Biosciences, Incyte, Infinity Pharmaceuticals, Janssen, Juno Therapeutics, Karyopharm Therapeutics, Kite Pharma, Loxo, Merck, MorphoSys, Novartis, Pfizer, Pharmacyclics, Portola Pharmaceuticals, Rhizen Pharmaceuticals, Roche, Seattle Genetics, Takeda, Teva, TG Therapeutics, Trillium Therapeutics, Triphase Research & Development Corp., Unum Therapeutics, and Verastem but his honorarium is issued to his institution, Sarah Cannon Research Institute.

Amy L Goodrich, RN, MSN, CRNP-AC–has disclosed that she is a consultant/on the advisory board for Abbvie, AstraZeneca, Celgene, and Rigel.

Matthew Lunning, DO–has disclosed that he is a consultant for Acrotech, ADC Therapeutics, AstraZeneca, BeiGene, BMS, Daiichi Sankyo, Janssen, Karyopharm, Kite, Kyowa Kirin, Legend, Morphosys, Myeloid Therapeutics, Novartis, Spectrum, and TG Therapeutics.

Shazia K. Nakhoda, MD–has no relevant financial relationships to disclose in relation to the content of this activity.

Barbara Rogers, CRNP, MN, AOCN, ANP-BC–has disclosed that she is a consultant for ADCC Therapeutics, Cardinal Health, and Coherus. She is on the speakers' bureau for AstraZeneca and Coherus.

Julie Vose, MD, MBA–has disclosed that she is a consultant for Abbvie, Acerta Pharma/AstraZeneca, Conjupro Biotherapeutics, Genentech, Janssen/Pharmacyclics, Johnson and Johnson, Kite Pharma, Morphyosis, Oncternal, Roche, and Vaniam Group. She receives grant/research support from Acerta Pharma/AstraZeneca, Celgene/BMS, Epizyme, Incyte Corp., Kite Pharma, LOXO, Novartis, and Seattle Genetics, Inc.

Reviewer:
Beth Faiman, PhD, MSN, APRN-BC, AOCN, FAAN–has no relevant financial relationships to disclose in relation to the content of this activity.

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

 

Nursing (ANCC)
This activity is designated for 1.0 contact hour.

Upon completion of an evaluation and credit request, statements of credit for nurses will be issued automatically.

ONCC/ILNA Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. OCN®, AOCNP®, CBCN®, CPHON®, and BMTCN® nurses may apply 1.0 point in Care Continuum, Care of the Pediatric Hematology and Oncology Patient, Diagnosis and Staging, Disease-Related Biology, Oncologic Emergencies, Oncology Nursing Practice, Quality of Life, Psychosocial, Scientific Basis for Practice, Survivorship, Symptom Management, and Treatment categories. 

Disclaimer: ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. 

Available Credit

  • 1.00 ANCC
    • 0.75 ANCC Pharmacology Contact Hours
  • 1.00 Participation
Please login or register to take this course.